An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Someone asked which of a list of so-called nootropics — things like Semax, Selank, Dihexa, PRL-8-53, NSI-189, TAK-653, plus phenibut and methylene blue — actually have real human evidence behind them, and which are mostly animal studies or anecdote. They also wanted to know if these substances overlap in how they work and whether mixing them matters, especially since they already take Adderall. The short answer: most of these have very limited or preliminary human data; a few have small human studies, many are tested only in animals, and combining them with prescription stimulants raises unknown safety questions. Semax and Selank are short synthetic peptides developed in Russia. Semax is modeled on a fragment of a natural protein involved in brain signaling and is mainly studied for attention, memory, and recovery after strokes. Selank is similar but was designed with anxiety and immune effects in mind. Dihexa is a peptide derived from a fragment of a natural brain protein and is promoted because it may boost connections between brain cells (synapses) in animal studies. PRL-8-53, NSI-189 and TAK-653 are small molecules investigated as cognitive enhancers or antidepressants; PRL-8-53 has one small human trial from decades ago suggesting a short memory boost, NSI-189 has had a few early human trials for depression, and TAK-653 is in early clinical testing as an antidepressant. Phenibut is a GABA-like compound used for anxiety and sleep (and can cause dependence). Methylene blue is an old dye with some biological effects; low-dose forms are sometimes studied for cognitive effects. When you look at the actual research, the pattern is small, mixed, and often animal-heavy. Semax and Selank have more human use in Russia, with some clinical and experimental studies reporting modest effects on attention, mood or recovery, but many of those studies are small and not replicated widely in Western journals. Dihexa’s promising synapse-building effects are in rodents; human data are essentially absent. PRL-8-53’s human evidence is a single small study showing a modest memory improvement in a subset of people. NSI-189 reached small phase I/II trials with tentative signals in depression but no clear, replicated benefit yet. TAK-653 is in early-stage human trials but not proven. Phenibut has clear human effects (sedation, anxiolysis) but also a well-documented risk of dependence and withdrawal. Overall, most claims are preliminary and effect sizes, when reported, tend to be small or inconsistent. Why this matters: if you’re trying to boost attention, motivation or clarity, it’s important to know which choices rest on solid human evidence and which are experimental. For someone already on Adderall, adding peptides or research chemicals could change how you feel, increase side effects, or interact in ways that aren’t well studied. People seeking reliable improvement should prioritize well-studied approaches first: sleep, exercise, diet, therapy, and medications prescribed and monitored by a doctor. If you’re tempted by these compounds, know that for most of them you’re experimenting with very limited data. Caveats and risks: many of these substances aren’t approved in the U.S. for cognitive enhancement and may be sold without regulation. Side effects vary — phenibut can cause dependence and severe withdrawal; methylene blue can interact dangerously with antidepressants (serotonergic drugs) and can cause side effects; peptides may be contaminated or dosed inconsistently when bought online. Importantly, mixing untested compounds with stimulants like Adderall raises unknown risks, including increased anxiety, blood pressure, heart rate, or unexpected brain chemistry effects. If you’re considering anything beyond approved treatments, talk with a knowledgeable clinician, ideally one familiar with pharmacology, and be cautious about sourcing, dosing, and monitoring. Bottom line: a few of these agents have tiny human studies or clinical use in limited contexts, but most are supported mainly by animal work or anecdote, and combining them — especially with prescription stimulants — carries uncertain risks.
Source: r/Nootropics